Abstract

Abstract Epithelial-mesenchymal transition (EMT) is a developmental process that is aberrantly activated in cancers such as pancreatic ductal adenocarcinoma (PDAC) to promote disease progression and chemoresistance. EMT occurs heterogeneously among PDAC ductal cells, which frustrates efforts to identify the underlying signaling regulatory mechanisms. We hypothesize that cell-to-cell variation in the activities of specific signaling pathways explains EMT heterogeneity. To test this, we developed a workflow integrating: 1) iterative indirect immunofluorescence imaging (4i) to quantify the activities of up to seven purported EMT-regulating pathways with single-cell resolution and 2) a multivariate mutual information computational model to predict the pathways that are most informative of the EMT phenotype. In cultured PDAC cells, EMT was induced by treating cells with growth factors present in the tumor microenvironment (hepatocyte growth factor, epidermal growth factor, transforming growth factor β1, or two combinations) or with chemotherapeutics (gemcitabine or 5-fluorouracil). EMT phenotypic markers and signaling pathway proxies were assessed daily for up to 96 hr. A mutual information analysis of the aggregated data identified ERK as the most important signaling node explaining EMT heterogeneity across the diverse set of agonists investigated. Kinase inhibition and siRNA studies confirmed the implied role of ERK but also revealed a compensatory, EMT-driving JNK activation in the context of MEK inhibition that explains a cooperative effect of simultaneous MEK and JNK inhibition on EMT antagonism. Importantly, a model based on cell population-level measurements nominated JNK as more informative than ERK for determining EMT state in response to growth factors. We are implementing this approach in vivo using pancreas cancer tissue sections to determine generalizability of these findings in different microenvironmental contexts. Overall, our results demonstrate the pervasive importance of ERK for diverse drivers of EMT and the need to account for the effects of heterogeneous signaling pathway activation in the determination of EMT. Citation Format: Michelle C. Barbeau, Matthew J. Lazzara. MAPK signaling is a conserved mechanism explaining phenotypic heterogeneity across diverse drivers of epithelial-mesenchymal transition in pancreas cancer [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Pancreatic Cancer; 2023 Sep 27-30; Boston, Massachusetts. Philadelphia (PA): AACR; Cancer Res 2024;84(2 Suppl):Abstract nr A107.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call